Yo-Yo Approvals? Maybe Accelerated Approval Isn’t Fixed After All
Executive Summary
Oncopeptides’ reversal on Pepaxto may or may not prove to be the right decision – but it underscores the inherent limits to US FDA’s efforts to police ‘dangling’ accelerated approvals.